

Roche launches Ventana HER2 Dual ISH DNA probe assay

April 25, 2019—[Roche](#) has introduced the Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer patients to aid in determining who might be eligible for the targeted drug trastuzumab (Herceptin, Roche). The assay is being launched in Europe, the Middle East, Africa, Latin America, and Asia Pacific, and will be submitted to the U.S. Food and Drug Administration for approval.

“The new Ventana HER2 Dual ISH assay advances Roche’s commitment to personalized health care by delivering critical information on treatment options for breast and gastric cancer patients faster,” Michael Heuer, CEO of Roche Diagnostics, said in a press release. “Quick results are crucial in the fight against cancer, and every additional day that a clinician and a patient must wait for test results is a day too long.”

The assay is designed to be completed on the same day, and results can be read using light microscopy.